Serotonin and Noradrenaline Reuptake Inhibitors (SNRI)

Study	Exclusion reasons	Rmk	Reference
Michel, 2023	not relevant exposure	EXCLUCED: Due to limitations to the sample size, subgroup analyses were performed for PPIs, SSRIs, and dimenhydrinate only, with 26, 29, and 16 exposed participants, respectively. => No data for SNRIs.	Michel, H. Front. Pharmacol. 2023; 14:1051-. 10.3389/fphar.2023.1193317
Källen - Duloxetine, 2013	same data already obtained by other studies	Overlapping: For malformations: 3 studies kept from Sweden: Ankarfeld (Sweden/Denmark: 2004 - 2016); Furu 2015 (2006-2010 with other countries) and Reis 2010 (1995 - 2007). Kallen 2013 (Duloxetine 1996-2011) largely overlapped with these studies.	Källen B Pharmaceuticals (Basel) 2013;6:1221-86 10.3390/ph6101221
Lennestal, 2007	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Analysis of all antidepressant drugs with noradrenergic and varying serotonergic activity (serotonin-noradrenaline reuptake inhibitor [SNRI]/noradrenergic reuptake inhibitor [NRI] drugs). Inclusion of SNRI and others (as mirtazapine).	Lennestal J Clin Psychopharmacol 2007; 27:607-13 10.1097/jcp.0b013e31815ac4d2
Viguera, 2023	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: analysis of mothers who had taken an SSRI and/or SNRI during their pregnancy, as a whole, without distinction between SSRI and SNRI.	Viguera J Clin Psychiatry 2023; 84: 10.4088/JCP.22m14492
Källen, 2006	Studies without separate analysis of the considered drug/class from other drugs/class	EXCLUDED: Results for Venlafaxine provided in the group of 'other antidepressants' as a whole, without distinction between substances.	Källen Reprod Toxicol 2006; 21:221-2 10.1016/j.reprotox.2005.11.006